Press Releases

InVivo Therapeutics Announces Ben Taub Hospital/Baylor College of Medicine as New Site for INSPIRE Study

Published: July 18, 2016

CAMBRIDGE, Mass. (July 18, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that the Ben Taub Hospital in Houston, TX has been added as a clinical site for The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury. The Ben Taub Hospital, located in the heart of the Texas Medical Center, is staffed by the Baylor College of Medicine and is the central clinical care facility for the Harris Health System. “I’m thrilled to bring the INSPIRE study to the Ben Taub Hospital,” […]

View Article
InVivo Therapeutics Opens First Ex-U.S. Site in Canada for INSPIRE Study

Published: July 14, 2016

Leading Spinal Cord Researcher Dr. Michael Fehlings and Toronto Western Hospital Join INSPIRE CAMBRIDGE, Mass. (July 14, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that it has received approval from the Toronto Western Hospital’s Research Ethics Board to enroll patients as part of the INSPIRE study. Michael Fehlings, M.D., Ph.D., has been named Principal Investigator at the site. Dr. Fehlings is currently Director of the Spinal Program at Toronto Western Hospital at the University Health Network, Professor in the Department of Surgery, full member  of  the  Institute  of Medical Sciences School of Graduate Studies, a Scholar in the […]

View Article
InVivo Therapeutics Receives Investigational Testing Authorization from Health Canada

Published: July 13, 2016

CAMBRIDGE, Mass. (July 13, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that Health Canada has approved the company’s Investigational Testing Authorization application to commence clinical studies in Canada. The authorization will allow the company to enroll Canadian patients into the ongoing INSPIRE study once a Canadian site is open for enrollment. InVivo currently is in late stage conversation with various Canadian Research Ethics Boards and expects to announce its first Canadian site in the coming weeks. “The Canadian scientific and medical community recognizes spinal cord injury as a significant unmet medical need and has been at the forefront of […]

View Article
InVivo Therapeutics Announces Update on the INSPIRE Study and FDA Approval of Expansion of the Study to 20 Evaluable Patients

Published: July 12, 2016

CAMBRIDGE, Mass. (July 12, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today provided an update on the INSPIRE study of the Neuro-Spinal Scaffold™. Patient Enrollments InVivo announced that the 9th and 10th patients have been implanted with the Neuro-Spinal Scaffold in the INSPIRE study. The 9th patient was implanted at Vidant Medical Center, a Level 1 trauma center located in Greenville, North Carolina. The implantation was performed by Vidant Medical Group neurosurgeons Stuart Lee, M.D., the Principal Investigator at the site, and Hilal Kanaan, M.D., approximately 40 hours after the injury occurred. Dr. Lee said, “The implantation procedure went smoothly […]

View Article
InVivo Therapeutics to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference

Published: July 8, 2016

CAMBRIDGE, Mass. (July 8, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that Christopher McNulty, Senior Vice President of Business Development and Investor Relations, is scheduled to present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference to be held July 12-13, 2016 at Le Parker Méridien Hotel in New York City, NY. The company’s presentation will be Tuesday, July 12th at 3:30 PM EDT. “We are pleased to present at Cantor’s healthcare conference two years in a row. This forum affords us the opportunity to connect with both the financial industry and other thought leaders in the space,” Mark Perrin, InVivo’s […]

View Article
InVivo Therapeutics to Present at 34th Annual Symposium of the National Neurotrauma Society

Published: June 23, 2016

CAMBRIDGE, Mass. (Jun 23, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that Richard Layer, Ph.D., InVivo’s Senior Director of Research, will be giving a poster presentation at the National Neurotrauma Society (NNS) 2016 Symposium to be held June 26-29 in Lexington, KY. The abstract, titled “Biodegradable Neuro-Spinal Scaffold™ Promotes Neuropermissive Tissue Remodeling Following Spinal Contusion Injury in Rats” will be published electronically in the Journal of Neurotrauma immediately prior to the conference. “It’s important to continue to raise awareness about our novel approach to treating spinal cord injuries. We look forward to our participation in the NNS symposium […]

View Article
InVivo Therapeutics Announces Publication in Neurosurgery of Case Report Detailing First Neuro-Spinal Scaffold™ Implantation

Published: June 22, 2016

CAMBRIDGE, Mass. (Jun 22, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced the publication of a case report in the journal Neurosurgery detailing the first clinical Neuro-Spinal Scaffold implantation. Neurosurgery is the official journal of the Congress of Neurological Surgeons. Nicholas Theodore, M.D., is the lead author of the article, titled, “First Human Implantation of a Bioresorbable Polymer Scaffold for Acute Traumatic Spinal Cord Injury: A Clinical Pilot Study for Safety and Feasibility.” The article describes the clinical presentation, surgical procedure, and postoperative improvement of the first patient in the INSPIRE study through the patient’s 6-month follow-up. Dr. Theodore said, “I am gratified that the […]

View Article
InVivo Therapeutics Announces Appointment of Christina Morrison to its Board of Directors

Published: June 8, 2016

CAMBRIDGE, Mass. (Jun 8, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Christina Morrison to its Board of Directors effective immediately. Most recently, Ms. Morrison served as the Senior Vice President of Finance for Aramark, where she was responsible for treasury, including oversight of over $5 billion of debt, global shared services, which processes certain accounting functions as well as certain human resource functions for over 120,000 employees, and mergers & acquisitions. She joined Aramark in June 2013 as Senior Vice President of Finance. Prior to joining Aramark, Ms. Morrison was Senior Vice President of Business and […]

View Article
InVivo Therapeutics Featured on CBS Radio Affiliate

Published: May 26, 2016

- Industry Veteran Jeff Brown Interviews CEO and Chairman Mark Perrin on WBZ NewsRadio 1030 in Boston – CAMBRIDGE, Mass. (May 26, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that the company was featured in a WBZ NewsRadio 1030 (CBS – Boston) interview with New England Business reporter Jeff Brown. Mr. Brown has been with WBZ NewsRadio since 2012 and is a 30-year veteran of the broadcast industry.  The interview aired a number of times on May 23 and May 24 with a total audience reach of nearly a half million listeners. “It was a pleasure to share details […]

View Article
InVivo Therapeutics Announces Notice of Allowance for Patent Covering Methods of Treating Spinal Cord Injuries Using a Broad Array of Polymeric Implants, Including the Neuro-Spinal Scaffold™

Published: May 18, 2016

CAMBRIDGE, Mass. (May 18, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that a Notice of Allowance has been received from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application No. 14/694,466, titled “Methods and Compositions for the Treatment of Open and Closed Wound Spinal Cord Injuries”. The application covers methods of treatment of compression or contusion spinal cord injuries with a broad array of biodegradable and/or bioabsorbable polymeric implants that includes InVivo’s Neuro-Spinal Scaffold™, which is currently being studied in the pivotal INSPIRE study. Of note, the allowed claims cover methods of use for a broader spectrum of polymeric compositions than claims […]

View Article

The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on the InVivo website for historical purposes only. InVivo assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.